Evidence map›Paper›PMID 42006369›Full record

ArticleiScience2026

pH-responsive Folate-PEG modified ZIF-8 Nanoparticles deliver fisetin to Aquaporin-3 for cervical cancer therapy.

Hanlin Yang, Weiwei Li, Hailong Zhang, Yameng Liu, Miaomiao Cui, Yurong Zhu, Li Hou, Shaoju Min, Jie Ren, Yujie Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanlin YangCentre for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
Weiwei LiDepartment of Laboratory Medicine, Guiyang Maternity & Child Health Hospital, Guiyang 550001, China.
Hailong ZhangSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang 550004, China.
Yameng LiuSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang 550004, China.
Miaomiao CuiDepartment of Clinical Laboratory, The Affiliated JINYANG Hospital of Guizhou Medical University, Guiyang 550081, China.
Yurong ZhuSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang 550004, China.
Li HouCentre for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
Shaoju MinCentre for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
Jie RenDepartment of Gynecology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
Yujie TanCentre for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional cervical cancer therapies often cause severe side effects and face recurrence challenges. Although the natural flavonoid fisetin (FIS) exhibits strong anticancer properties, its clinical utility is restricted by poor aqueous solubility. To overcome this, we engineered a tumor-targeting nanotherapeutic, PEG-FA@ZIF-8@FIS, by encapsulating FIS within a zeolitic imidazolate framework-8 (ZIF-8) core surface-functionalized with polyethylene glycol-folic acid (PEG-FA). Both

Indexed as

biological sciencesbiomaterialscancerdrug delivery systemnanoparticles

Identifiers

PMID42006369
PMCPMC13091531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.